Protagenic Therapeutics, Inc. Files Form 8-K: Key Details for Investors

Protagenic Therapeutics, Inc. (OTC: PTIX) has filed a Form 8-K with the Securities and Exchange Commission, dated March 31, 2026. This filing represents a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934, which companies use to disclose major events that shareholders need to be aware of. Below are the detailed highlights and implications for investors:

Key Points from the 8-K Filing

• Company Details: Protagenic Therapeutics, Inc. is headquartered at 149 Fifth Avenue, Suite 500, New York, NY 10010. The company’s main contact number is (212) 994-8200.
• Security Information:
  • Common Stock: The company’s common stock is listed on the OTC Markets under the trading symbol PTIX.
  • Common Stock Warrants: The warrants are listed under the symbol PTIXW on the OTC Markets.
• Emerging Growth Company Status: Protagenic Therapeutics, Inc. has indicated it is not an emerging growth company. This means it does not qualify for certain regulatory exemptions, which could impact its reporting obligations and access to capital markets.
• SEC Compliance: The filing confirms that the company is compliant with its SEC reporting obligations. There are no indications of bankruptcy proceedings or material legal issues.

Regulatory and Price Sensitive Disclosures

• No Written Communications, Soliciting Material, or Tender Offers: The 8-K report explicitly states that there are no written communications under Rule 425, no soliciting materials under Rule 14a-12, and no pre-commencement tender offers under Rules 14d-2(b) or 13e-4(c). This means there are no major acquisition, merger, or tender offer activities disclosed in this filing.
• Corporate History: Protagenic Therapeutics, Inc. has undergone several name changes in the past (formerly Atrinsic, Inc., New Motion, Inc., MPLC, Inc.), but no new corporate actions or changes are disclosed in this report.
• Item 5.02 Departure/Election of Directors or Officers: The form includes Item 5.02, which is typically used to report changes in management or compensatory arrangements for officers. However, the filing does not provide any details of director or officer departures, appointments, or new compensation agreements. Investors should note that if such information is provided in a future update, it could be material and price-sensitive.
• Shareholder Impact: There are no new material events, transactions, or changes disclosed in this filing that would directly impact shareholders or alter the valuation of PTIX shares. The report appears to be routine and primarily administrative in nature.

Implications for Investors

• The lack of material corporate actions or price-sensitive disclosures in this filing suggests no immediate impact on the company’s share value.
• Investors should monitor subsequent filings for any updates regarding management changes, corporate transactions, or new capital raises, as these could be significant for PTIX’s future prospects.
• The confirmation of SEC compliance and proper registration of securities provides assurance of continued trading eligibility on OTC Markets.

Conclusion

Based on the information provided in this Form 8-K, there are no newsworthy events or price-sensitive disclosures that would materially affect Protagenic Therapeutics, Inc.’s share value at this time. The filing is primarily administrative and confirms the company’s compliance with regulatory requirements.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial professionals before making investment decisions. The information is based on the latest SEC filings and may be subject to change. No responsibility is taken for any actions made based on this article.

View Protagenic Therapeutics, Inc.new Historical chart here